<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>E药经理人 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-14T20:23:20+08:00</updated>
  <subtitle>我们致力于成为医药行业意见领袖平台，我们记录和观察医药重大商业事件，展现这个行业的复杂和冲突，提供最前线的思想火花。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>医保谈判DAY1：降幅超预期，多为独家品种，涉诺华、礼来。PD-1或在第三天</title>
    <updated>2020-12-14T19:23:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/2rhvxukVFpLpVgdchHt9Vw</id>
    <link href="https://mp.weixin.qq.com/s/2rhvxukVFpLpVgdchHt9Vw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>专访亚盛医药首席商务运营官祝刚：港股原创小分子第一股的商业经</title>
    <updated>2020-12-14T19:23:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/SPvSVI_7vJQAm0D3M9f9cg</id>
    <link href="https://mp.weixin.qq.com/s/SPvSVI_7vJQAm0D3M9f9cg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>氟唑帕利的前世今生——恒瑞医药李心博士专访</title>
    <updated>2020-12-14T19:23:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/ScEkC5MQHvMvy81FT3JEmw</id>
    <link href="https://mp.weixin.qq.com/s/ScEkC5MQHvMvy81FT3JEmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>聚产业力量，创产业未来 ——中国医药产业链首个品牌服务商联盟发起成立</title>
    <updated>2020-12-14T19:23:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/FomOK7F5AfxYIssUPBPrWQ</id>
    <link href="https://mp.weixin.qq.com/s/FomOK7F5AfxYIssUPBPrWQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康豪掷2500亿拟收购罕见病巨头，今年最大收购！</title>
    <updated>2020-12-13T20:48:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/pVNd4NBAno7zFPOMa8jq7g</id>
    <link href="https://mp.weixin.qq.com/s/pVNd4NBAno7zFPOMa8jq7g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>3800亿市值京东健康，来看看10万亿的亚马逊如何布局医药健康！</title>
    <updated>2020-12-13T20:48:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-13:/s/vbBj1ryM4zgl5SgvX6KBLA</id>
    <link href="https://mp.weixin.qq.com/s/vbBj1ryM4zgl5SgvX6KBLA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年创新药热门靶点盘点！谁是下个PD-(L)1？谁能颠覆目前格局？</title>
    <updated>2020-12-12T19:05:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/nUSGzszhisAUcAki9nSz8w</id>
    <link href="https://mp.weixin.qq.com/s/nUSGzszhisAUcAki9nSz8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>单笔融资超3亿美元！AI+药物研发迎来新拐点？</title>
    <updated>2020-12-12T19:05:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/E6og76sUFKrDZhZBDpEzMg</id>
    <link href="https://mp.weixin.qq.com/s/E6og76sUFKrDZhZBDpEzMg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康与艾德生物携手推进县域肿瘤精准诊疗 惠及基层医患</title>
    <updated>2020-12-12T19:05:41+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-12:/s/3N2OCUN2EXmgoJTFjjB_rw</id>
    <link href="https://mp.weixin.qq.com/s/3N2OCUN2EXmgoJTFjjB_rw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞第七款创新药获批在即，直面百济、再鼎与AZ！进击全球TOP15！</title>
    <updated>2020-12-11T17:35:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/G-mwe2waksBbmg7HuUeWkw</id>
    <link href="https://mp.weixin.qq.com/s/G-mwe2waksBbmg7HuUeWkw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>日本媒体眼中的中国集采和“败”下阵来的卫材、参天、科研</title>
    <updated>2020-12-11T17:35:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/V6m1Bwx1dJZLcWBg0N3T5Q</id>
    <link href="https://mp.weixin.qq.com/s/V6m1Bwx1dJZLcWBg0N3T5Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医保局考虑把更多罕见病用药纳入集采，涉及杨森、诺和诺德等数十亿美元品种！</title>
    <updated>2020-12-11T17:35:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/QwOKNbk4QTd0yx9pZQTCeA</id>
    <link href="https://mp.weixin.qq.com/s/QwOKNbk4QTd0yx9pZQTCeA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>研发30年，致敬诺奖级肿瘤疗法！</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/-JcW3DGzwwNFEvYayt3W4w</id>
    <link href="https://mp.weixin.qq.com/s/-JcW3DGzwwNFEvYayt3W4w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第四批集采：44品种，谁竞争最激烈？谁价格最低？谁市场最大？谁最波折？替格瑞洛为何二次进集采？</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/9yH2QXT9ln8Ie5eBB0ftUQ</id>
    <link href="https://mp.weixin.qq.com/s/9yH2QXT9ln8Ie5eBB0ftUQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>你会接种新冠疫苗吗？辉瑞疫苗存隐患，志愿者接种后出现副作用。</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/h6Jj_2A4aLLCldT_hPx3qw</id>
    <link href="https://mp.weixin.qq.com/s/h6Jj_2A4aLLCldT_hPx3qw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>智慧医疗投资，赢在何方？挑战是什么？</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/7EyWVoiCiH4SngV0bLjjYw</id>
    <link href="https://mp.weixin.qq.com/s/7EyWVoiCiH4SngV0bLjjYw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>投资人视角|提高直接融资比重，强化资本市场功能</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/irAwosrB0FZgZi8FqL704w</id>
    <link href="https://mp.weixin.qq.com/s/irAwosrB0FZgZi8FqL704w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>众多十亿美元级品种入选四批集采，这些药企涉及产品最多！这几个热门品种却没纳入！</title>
    <updated>2020-12-09T17:48:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/fB7l4_Et5g4IefNsUHsx7w</id>
    <link href="https://mp.weixin.qq.com/s/fB7l4_Et5g4IefNsUHsx7w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球问世30年，这项革命性分子互作技术为什么能成为行业金标准？</title>
    <updated>2020-12-09T17:48:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/6YnxY3BkvHov-bfIXa9-6w</id>
    <link href="https://mp.weixin.qq.com/s/6YnxY3BkvHov-bfIXa9-6w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首个用于治疗系统性红斑狼疮的靶向生物制剂贝利尤单抗获批儿童适应症，惠及五岁及以上患儿</title>
    <updated>2020-12-09T17:48:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/Hlx9sAG5U5QQ3UkTjIqoGQ</id>
    <link href="https://mp.weixin.qq.com/s/Hlx9sAG5U5QQ3UkTjIqoGQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>